Figure 3.
Clinical improvement of AD and AA by dupilumab treatment. (a–d) Representative case of AA with extrinsic AD before and 6 months after dupilumab therapy. (e,f) Changes of EASI scores (e) and SALT scores (f) in 6 patients with extrinsic AD and AA before and 6 months after dupilumab therapy. (g–j) Representative case of AA with extrinsic AD before and 6 months after dupilumab therapy. (k) The CXCR3/CCR4 ratio in the AA patients with extrinsic AD.